A carregar...

EXTH-72. CONTINUOUS INFUSION STUDIES REVEAL THE POTENCY OF ELACRIDAR TO ACT AS A PHARMACO-ENHANCER FOR TREATMENT OF INTRACRANIAL DISEASES BY INHIBITING ABCB1 AND ABCG2 AT THE BLOOD-BRAIN BARRIER

The blood-brain barrier (BBB) is a formidable hurdle to successful pharmacotherapy of intracranial diseases. ABCB1 and ABCG2 are efflux transporters that play an important role in the BBB, keeping substances out of the brain. Elacridar and tariquidar are third-generation ABCB1-inhibitors developed f...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: van Tellingen, Olaf, de Gooijer, Mark C, Zuidema, Stefanie, Meurs, Amber, Çitirikkaya, Ceren H, Venekamp, Nikkie, Beijnen, Jos H
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651375/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.426
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!